Art Biktarvy denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for art biktarvy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Biktarvy as Non-Formulary — and Why You Can Appeal

Blue Cross Blue Shield non-formulary denials for Biktarvy (bictegravir/tenofovir alafenamide/emtricitabine) mean the plan's drug formulary does not include Biktarvy at a covered tier, or places it at a tier requiring prior authorization or a formulary exception. Plans typically maintain formulary-preferred HIV regimens as cost-management tools. However, formulary exceptions are routinely available when a prescriber documents that the preferred alternatives are not clinically appropriate for a specific patient.

This is one of the most commonly overturned denial types for HIV regimens. The ACA requires non-grandfathered plans to have a formulary exception process.

## The Federal Appeal Framework

• ACA §2719 External Review: After internal appeal exhaustion, independent external review is available. Filing deadline is typically around 180 days from the denial notice — verify the exact date on your denial letter.
• ERISA §503 (employer-sponsored plans): Full-and-fair review right, with written explanation of plan provisions relied upon.
• Formulary Exception Process (ACA): Non-grandfathered plans must grant a formulary exception if the preferred drug is not clinically appropriate for the patient and the requested drug is medically necessary.
• Expedited review: Invoke if a gap in HIV therapy would seriously jeopardize health. Decisions typically required within 72 hours.

## What to Gather

1. Trial of formulary-preferred alternatives — documentation showing you have tried the plan's preferred HIV regimen(s) and the outcome; or a prescriber explanation of why each preferred alternative is not clinically appropriate for you (intolerance, resistance, drug interaction, comorbidity). 2. Prescriber medical-necessity and formulary-exception letter — should name each formulary-preferred alternative and explain specifically why it is not appropriate for this patient, then affirmatively justify Biktarvy. 3. Relevant resistance testing — if applicable, genotypic or phenotypic results that support the need for Biktarvy's specific component agents. 4. Diagnosis and treatment history — chart documentation of HIV-1 diagnosis, current viral status, and full antiretroviral history. 5. BCBS's formulary exception criteria — obtain the plan's published exception process and copy the requirements into your appeal, answering each with specific chart evidence.

## Criteria-Mapping Structure

| BCBS Formulary Exception Requirement | How Your Situation Satisfies It | |---|---| | [Paste each criterion from the formulary exception policy] | [Chart note, lab result, prescriber statement addressing it] |

## Next Steps

File the formulary exception request and internal appeal simultaneously, with the full documentation package. A prescriber peer-to-peer call with the plan's medical director is especially productive for non-formulary exceptions. If denied, external review is available and independent reviewers frequently grant exceptions when the clinical record is well-documented.